METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo targets hard-to-treat breast cancer in patients with metabolic problems
Disease control Recruiting nowThis study tests whether adding the experimental drug evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better than chemotherapy alone for people with metastatic triple-negative breast cancer who also have metabolic dysfunction (like insulin resistance). About 55 p…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New hope for tough breast cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis study tests two different drug combinations for people with metastatic triple-negative breast cancer that has not responded to one prior treatment. The goal is to see if adding immunotherapy drugs to a targeted chemotherapy can help control the cancer longer. About 60 adults…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy targets hard-to-treat breast cancer
Disease control Recruiting nowThis study tests two drugs, naxitamab and sacituzumab govitecan, together in people with metastatic triple-negative breast cancer (cancer that has spread). The goal is to find the safest dose and see if the combination helps control the disease. About 31 adults with this type of …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC